The top pharmaceutical companies are blurring the lines with biotech and have been engaging in many collaborations, acquisitions, and restructuring plans in the past year.

Humira

Humira during 2014 remained the world’s best-selling prescription medicine; Sovaldi vaulted into second place in its first full year on the market; Harvoni is challenging Humira for the 2015 sales crown.

The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.

As the pipelines of their pharmaceutical and biotech clients continue to yield new drugs for patients, agencies are also seeing their business grow.

Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.

The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.

Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.

According to closerlook’s leaders, agency growth in 2013 reflects the value of its commitment to smarter marketing. Investments in the agency’s services by new and existing clients led to increases of 44 percent in revenue and 56 percent in staff – including the creation of several c-suite positions.

The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies.

From big pharma to smaller specialty entities, contract manufacturing serves as a strategy for various industry players.